Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

6
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

Movapo

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Drugs for Parkinson's disease. Med Lett Drugs Ther 2021;63:25-32. [PMID: 33647001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023] Abstract Collapse Key Words Apokyn Aricept Azilect Clozaril Cogentin Comtan Duodopa Duopa Ebixa Eldepryl Exelon Gocovri Inbrija Kynmobi Lodosyn Mirapex Movapo Namenda Neupro Nourianz Nuplazid Ongentys Onstryv Osmolex Parkinson's disease Parlodel Razadyne Requip Rytary SNRIs SSRIs Seroquel Sinemet Stalevo Tasmar Xadago Zelapar Zofran adverse effects amantadine apomorphine benztropine bromocriptine carbidopa carbidopa/levodopa clozapine deep brain stimulation depression donepezil dosage drug interactions efficacy entacapone galantamine istradefylline levodopa memantine nortriptyline ondansetron opicapone pimavanserin pramipexole quetiapine rasagiline rivastigmine ropinirole rotigotine safety safinamide selegiline tolcapone trihexyphenidyl Collapse MESH Headings Antiparkinson Agents/administration & dosage Antiparkinson Agents/pharmacokinetics Carbidopa/administration & dosage Carbidopa/pharmacokinetics Catechol O-Methyltransferase/metabolism Dopaminergic Neurons/drug effects Dopaminergic Neurons/metabolism Dopaminergic Neurons/pathology Drug Therapy, Combination Humans Levodopa/administration & dosage Levodopa/pharmacokinetics Parkinson Disease/drug therapy Parkinson Disease/metabolism Parkinson Disease/psychology Collapse Grants Collapse Affiliation(s) Collapse
2	Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease. Med Lett Drugs Ther 2021;63:3-5. [PMID: 33646998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023] Abstract Collapse Key Words Apokyn Comtan Inbrija Kynmobi Movapo Nourianz Ongentys Parkinson's disease Rytary Stalevo Tasmar adverse effects apomorphine carbidopa/levodopa dopamine dosage drug interactions efficacy entacapone epinephrine istradefylline lactation levodopa opicapone phenelzine pregnancy safety selegeline tolcapone Collapse MESH Headings Antiparkinson Agents/metabolism Antiparkinson Agents/therapeutic use Catechol O-Methyltransferase/metabolism Catechol O-Methyltransferase Inhibitors/metabolism Catechol O-Methyltransferase Inhibitors/therapeutic use Clinical Trials as Topic/methods Humans Oxadiazoles/metabolism Oxadiazoles/therapeutic use Parkinson Disease/drug therapy Parkinson Disease/metabolism Collapse Grants Collapse Affiliation(s) Collapse
3	Comparison chart: Drugs for Parkinson's disease. Med Lett Drugs Ther 2020;62:e1-9. [PMID: 33647002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023] Abstract Collapse Key Words Apokyn Azilect Comtan Duodopa Duopa Eldepryl Gocovri Inbrija Kynmobi Lodosyn Mirapex Movapo Neupro Nourianz Ongentys Onstryv Osmolex Requip Rytary Sinemet Stalevo Tasmar Xadago Zelapar Zofran adverse effects amantadine apomorphine carbidopa carbidopa/levodopa dosage drug interactions efficacy entacapone istradefylline levodopa ondansetron opicapone pramipexole rasagiline ropinirole rotigotine safety safinamide selegiline tolcapone Collapse MESH Headings Antiparkinson Agents/adverse effects Antiparkinson Agents/pharmacokinetics Antiparkinson Agents/therapeutic use Carbidopa/adverse effects Carbidopa/pharmacokinetics Carbidopa/therapeutic use Catechol O-Methyltransferase/adverse effects Catechol O-Methyltransferase/pharmacokinetics Catechol O-Methyltransferase/therapeutic use Dopamine Agonists/adverse effects Dopamine Agonists/pharmacokinetics Dopamine Agonists/therapeutic use Humans Kidney Diseases/chemically induced Kidney Diseases/metabolism Levodopa/adverse effects Levodopa/pharmacokinetics Levodopa/therapeutic use Monoamine Oxidase Inhibitors/adverse effects Monoamine Oxidase Inhibitors/pharmacokinetics Monoamine Oxidase Inhibitors/therapeutic use Parkinson Disease/drug therapy Parkinson Disease/metabolism Collapse Grants Collapse Affiliation(s) Collapse
4	Sublingual apomorphine (Kynmobi) for Parkinson's disease. Med Lett Drugs Ther 2020;62:165-6. [PMID: 33429410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023] Abstract Collapse Key Words Apokyn Inbrija Kynmobi Movapo Nourianz Parkinson's disease Rytary Trimethobenzamide adverse effects apomorphine carbodipa/levodopa dosage drug interactions efficacy istradefylline lactation levodopa pregnancy safety Collapse MESH Headings Administration, Sublingual Antiparkinson Agents/administration & dosage Antiparkinson Agents/therapeutic use Apomorphine/administration & dosage Apomorphine/therapeutic use Double-Blind Method Female Humans Male Parkinson Disease/drug therapy Randomized Controlled Trials as Topic Collapse Grants Collapse Affiliation(s) Collapse
5	Istradefylline (Nourianz) for Parkinson's disease. Med Lett Drugs Ther 2020;62:20-3. [PMID: 32022788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Abstract Collapse Key Words Apokyn Azilect Comtan Duodopa Duopa Gocovri Inbrija Lodosyn Mirapex Movapo Neupro Nourianz Osmolex Parkinson's disease Prolopa Requip Rytary Sinemet Stalevo Tasmar Xadago Zelapar adverse effects amantadine apomorphine carbidopa carbidopa/levodopa dosage drug interactions efficacy entacapone istradefylline levodopa pramipexole rasagiline ropinorole rotigotine safety safinamide selegiline tolcapone Collapse MESH Headings Adenosine A2 Receptor Antagonists/administration & dosage Adenosine A2 Receptor Antagonists/adverse effects Adenosine A2 Receptor Antagonists/therapeutic use Antiparkinson Agents/administration & dosage Antiparkinson Agents/adverse effects Antiparkinson Agents/therapeutic use Carbidopa/administration & dosage Carbidopa/adverse effects Carbidopa/therapeutic use Clinical Trials as Topic Drug Administration Schedule Humans Levodopa/adverse effects Levodopa/therapeutic use Parkinson Disease/drug therapy Purines/administration & dosage Purines/adverse effects Purines/therapeutic use Collapse Grants Collapse Affiliation(s) Collapse
6	Inhaled levodopa (Inbrija) for Parkinson's disease. Med Lett Drugs Ther 2019;61:73-4. [PMID: 31169799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Abstract Collapse Key Words Apokyn Duopa Inbrija Movapo Parkinson's disease Rytary Sinemet adverse effects apomorphine carbidopa/levodopa dosage efficacy levodopa safety Collapse MESH Headings Administration, Inhalation Antiparkinson Agents/administration & dosage Antiparkinson Agents/adverse effects Antiparkinson Agents/pharmacology Carbidopa/administration & dosage Drug Combinations Dry Powder Inhalers Humans Levodopa/administration & dosage Levodopa/adverse effects Levodopa/pharmacology Parkinson Disease/drug therapy Parkinson Disease/physiopathology Treatment Outcome Collapse Grants Collapse Affiliation(s) Collapse